Prurigo Nodularis (PN) is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution. PN is accompanied by long-standing pruritus and thought to develop as a reaction to repeated scratching in patients with Chronic Prurigo (CP) from various etiologies, including dermatological, systemic, infectious, and psychiatric.
&nbsp;
The disease is characterized by hyperkeratotic, crusted or excoriated, light-red to bright-red papules, nodules or plaques with hyperpigmented margins as a distinguish features.
&nbsp;
Prurigo Nodularis Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Prurigo Nodularis in 7MM from 2017 to 2030 is segmented as:-&nbsp;
&bull; Diagnosed Prevalent Cases
&bull; Gender-specific Diagnosed Prevalence
&bull; Age-specific Diagnosed Prevalence
&bull; Type-specific Diagnosed Prevalence
&bull; Severity-specific Diagnosed Prevalence
&nbsp;
<a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/report-store/prurigo-nodularis-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Prurigo Nodularis Epidemiology</a>&nbsp;
&bull; The total diagnosed prevalent population in 7MM in 2017 was 539,893&nbsp;&nbsp;
&bull; The United States had the largest share of the total diagnosed prevalent population with ~46.30% of the total cases in 2017
&bull; EU5 countries occupied 38.31% of the patient pool amongst 7MM in 2017
&nbsp;
<a style="color: #0047b2; background-color: transparent;" href="https://www.delveinsight.com/report-store/prurigo-nodularis-market" target="_blank" rel="noopener noreferrer">Prurigo Nodularis Market</a>
The market size of Prurigo Nodularis in 7MM in 2017 was USD 659.29 Million&nbsp;
&nbsp;
Prurigo Nodularis Market Drivers
&bull; Government Initiatives
&bull; Pipeline Advancements and various off-label therapies
&bull; Growth in R&amp;D&nbsp;
&bull; Increase in the number of patients&nbsp;
&nbsp;
Prurigo Nodularis Market Barriers
&bull; Disease-related challenges in terms of pathophysiology and management
&bull; Lack of Clinical Trial Data
&nbsp;
<a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/report-store/prurigo-nodularis-pipeline-insight" target="_blank" rel="noopener noreferrer">Prurigo Nodularis Emerging Drugs</a>
The emerging drugs of the Prurigo Nodularis market are&nbsp;
&bull; Serlopitant
&bull; Nalbuphine ER
&bull; Nemolizumab (CD14152)
&bull; Apremilast (CC-10004)
&bull; M 118103
&bull; KPL-716
&bull; Dupixent (Dupilumab/SAR231893)
And many others.&nbsp;
&nbsp;
Prurigo Nodularis Key Players
The key players in the Prurigo Nodularis market are
&bull; Menlo Therapeutics
&bull; Trevi Therapeutics
&bull; Galderma
&bull; Amgen
&bull; Maruho
&bull; Kiniksa Pharmaceuticals
&bull; Sanofi
&bull; Regeneron Pharmaceuticals
And many others.&nbsp;

Prurigo Nodularis Market

Prurigo Nodularis Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.